NovaBridge Biosciences Doses First Patient in Pivotal Phase 2 Study for Lead Gastric Cancer Drug Givastomig

summarizeSummary

NovaBridge Biosciences announced the dosing of the first patient in its global, randomized Phase 2 study for Givastomig, a bispecific antibody for first-line metastatic gastric cancer, marking a critical advancement for its lead oncology candidate.

check_boxKey Events

• Phase 2 Study Initiated for Givastomig

  NovaBridge Biosciences has dosed the first patient in a global, randomized Phase 2 study evaluating Givastomig in combination with immunochemotherapy for first-line metastatic gastric cancer.

• Builds on Strong Phase 1b Data

  The Phase 2 study follows positive Phase 1b combination data, which demonstrated a 75% objective response rate (ORR) and a median progression-free survival (mPFS) of 16.9 months, positioning Givastomig as a potential best-in-class therapy.

• Significant Market Opportunity

  Givastomig targets a gastric cancer market projected to reach $12 billion by 2030, highlighting the substantial commercial potential of the drug.

• Topline Results Expected in 2027

  The company anticipates releasing topline results from the Phase 2 study in 2027, with updated Phase 1b dose expansion data expected in the second half of 2026.

auto_awesomeAnalysis

NovaBridge Biosciences has initiated a global Phase 2 study for Givastomig, its lead bispecific antibody targeting metastatic gastric cancer. This milestone is highly significant as it moves the company's most promising asset into a pivotal stage of clinical development, building on previously reported robust Phase 1b efficacy data. The drug is positioned as a potential best-in-class therapy for a gastric cancer market projected to reach $12 billion by 2030, underscoring its substantial commercial potential. Successful progression in this study could significantly de-risk the asset and drive future valuation.